Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DST-0509 in Thalassemia Patients Refractory to Chelation
NCT03637556Phase 2Completed
- Sponsor
- DisperSol Technologies
- Start
- Aug 2019
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of DST-0509 in Transfusional Iron Overload (TIO), sponsored by DisperSol Technologies. Started Aug 2019; status: completed.
02
Drugs
DST-0509
03
Conditions
Transfusional Iron Overload (TIO)
Beyond the preview
Go deeper on NCT03637556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03637556.